Astellas Gets Europe Okay For AML Drug Xospata
Pulls Further Ahead Of Daiichi Sankyo's Rival FLT3 Inhibitor
Following green lights in the US and Japan, Xospata has been approved for relapsed or refractory FLT3-positive acute myeloid leukemia. Getting first-line approval is the next step.
